BDSX Key Statistics, Chart & Performance
The current stock price of BDSX is 6.83 USD. In the past month the price increased by 1.49%. In the past year, price decreased by -73.32%.
BDSX Latest News, Press Relases and Analysis
BDSX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| CVS | CVS HEALTH CORP | 11.39 | 98.97B | ||
| CI | THE CIGNA GROUP | 9.79 | 74.23B | ||
| LH | LABCORP HOLDINGS INC | 16.79 | 22.07B | ||
| DGX | QUEST DIAGNOSTICS INC | 19.6 | 21.39B | ||
| BTSGU | BRIGHTSPRING HEALTH SERV - BTSG 6 3/4 02/01/27 | 108.86 | 19.67B | ||
| GH | GUARDANT HEALTH INC | N/A | 13.15B | ||
| DVA | DAVITA INC | 13.03 | 8.60B | ||
| HIMS | HIMS & HERS HEALTH INC | 64.28 | 7.85B | ||
| CHE | CHEMED CORP | 20.08 | 6.44B | ||
| RDNT | RADNET INC | 218.42 | 6.38B | ||
| BTSG | BRIGHTSPRING HEALTH SERVICES | 33.91 | 6.13B | ||
| OPCH | OPTION CARE HEALTH INC | 19.85 | 4.80B |
Related stock screener links
About BDSX
Company Profile
Biodesix, Inc. provides blood-based diagnostics services for patients with lung disease. The company is headquartered in Louisville, Colorado and currently employs 273 full-time employees. The company went IPO on 2020-10-28. Biodesix Diagnostic Tests, marketed as Nodify Lung Nodule Risk Assessment and IQLung Cancer Treatment Guidance, support clinical decisions to expedite personalized care and improve outcomes for patients with lung disease. Biodesix Development Services enable biopharmaceutical, life sciences, and research institutions with scientific, technological, and operational capabilities that fuel the development of diagnostic tests, tools, and therapeutics. The Nodify Lung Nodule Risk Assessment assesses a suspicious lung nodule's risk of lung cancer to help identify the most appropriate treatment pathway. Nodify CDT and Nodify XL2 tests are marketed as Nodify Lung Nodule Risk Assessment. The Nodify CDT test is a blood-based test that detects the presence of seven autoantibodies associated with the presence of tumors. GeneStrat ddPCR, GeneStrat NGS and VeriStrat tests are marketed as part of its IQLung testing strategy.
Company Info
BIODESIX INC
919 West Dillon Road
Louisville COLORADO US
Employees: 273
Phone: 13034170500
BIODESIX INC / BDSX FAQ
Can you describe the business of BIODESIX INC?
Biodesix, Inc. provides blood-based diagnostics services for patients with lung disease. The company is headquartered in Louisville, Colorado and currently employs 273 full-time employees. The company went IPO on 2020-10-28. Biodesix Diagnostic Tests, marketed as Nodify Lung Nodule Risk Assessment and IQLung Cancer Treatment Guidance, support clinical decisions to expedite personalized care and improve outcomes for patients with lung disease. Biodesix Development Services enable biopharmaceutical, life sciences, and research institutions with scientific, technological, and operational capabilities that fuel the development of diagnostic tests, tools, and therapeutics. The Nodify Lung Nodule Risk Assessment assesses a suspicious lung nodule's risk of lung cancer to help identify the most appropriate treatment pathway. Nodify CDT and Nodify XL2 tests are marketed as Nodify Lung Nodule Risk Assessment. The Nodify CDT test is a blood-based test that detects the presence of seven autoantibodies associated with the presence of tumors. GeneStrat ddPCR, GeneStrat NGS and VeriStrat tests are marketed as part of its IQLung testing strategy.
Can you provide the latest stock price for BIODESIX INC?
The current stock price of BDSX is 6.83 USD. The price increased by 4.92% in the last trading session.
What is the dividend status of BIODESIX INC?
BDSX does not pay a dividend.
What is the ChartMill rating of BIODESIX INC stock?
BDSX has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
How is the market expecting BDSX stock to perform?
11 analysts have analysed BDSX and the average price target is 35.7 USD. This implies a price increase of 422.69% is expected in the next year compared to the current price of 6.83.
Is BIODESIX INC (BDSX) expected to grow?
The Revenue of BIODESIX INC (BDSX) is expected to grow by 17.68% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the employee count for BDSX stock?
BIODESIX INC (BDSX) currently has 273 employees.
BDSX Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to BDSX. When comparing the yearly performance of all stocks, BDSX is a bad performer in the overall market: 94.81% of all stocks are doing better.
BDSX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to BDSX. BDSX has a bad profitability rating. Also its financial health evaluation is rather negative.
BDSX Financial Highlights
Over the last trailing twelve months BDSX reported a non-GAAP Earnings per Share(EPS) of -4.42. The EPS decreased by -1033.33% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -45.74% | ||
| ROE | -3530.7% | ||
| Debt/Equity | 41.23 |
BDSX Forecast & Estimates
11 analysts have analysed BDSX and the average price target is 35.7 USD. This implies a price increase of 422.69% is expected in the next year compared to the current price of 6.83.
For the next year, analysts expect an EPS growth of -1473.71% and a revenue growth 17.68% for BDSX